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Abstract. Neuroprotection of erythropoietin (EPO) following long-term administration is hampered by the associated undesirable
effects on hematopoiesis and body weight. For this reason, we tested carbamylated-EPO (CEPO), which has no effect on
erythropoiesis, and compared it with EPO in the APP/PS1 mouse model of familial Alzheimer’s disease. Groups of 5-month-
old wild type (WT) and transgenic mice received chronic treatment consisting of CEPO (2,500 or 5,000 UI/kg) or EPO (2,500
UI/kg) 3 days/week for 4 weeks. Memory at the end of treatment was assessed with the object recognition test. Microarray analysis
and quantitative-PCR were used for gene expression studies. No alterations in erythropoiesis were observed in CEPO-treated
WT and APP/PS1 transgenic mice. EPO and CEPO improved memory in APP/PS1 animals. However, only EPO decreased
amyloid- (A) plaque burden and soluble A40. Microarray analysis of gene expression revealed a limited number of common
genes modulated by EPO and CEPO. CEPO but not EPO significantly increased gene expression of dopamine receptors 1 and
2, and adenosine receptor 2a, and significantly down-regulated adrenergic receptor 1D and gastrin releasing peptide. CEPO
treatment resulted in higher protein levels of dopamine receptors 1 and 2 in WT and APP/PS1 animals, whereas the adenosine
receptor 2a was reduced in WT animals. The present results suggest that the improved behavior observed in APP/PS1 transgenic
mice after CEPO treatment may be mediated, at least in part, by the observed modulation of the expression of molecules involved
in neurotransmission.
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INTRODUCTION
Erythropoietin (EPO) is a glycoprotein hormone
with a well-known role in erythroid precursors. This
effect is triggered by hypoxia and is transduced through
binding of EPO to a homodimer of its receptor [1].
Cytoprotective functions for EPO have also been
described and these extend to a variety of cell types
including nervous tissue. The neuroprotective effects
of EPO have been described in acute experimental
brain injuries [2], and in experimental models of multi-
ple sclerosis [3], amyotrophic lateral sclerosis [4], and
Parkinson’s disease [5]. Clinical improvement has also
been reported in patients suffering from depression and
schizophrenia [6,7]. An equivalent to the mammalian
neuroprotective EPO system has been described in
insects showing its relevance and conservation dur-
ing evolution [8]. It is believed that EPO exerts its
neuroprotective effects through interaction with a het-
eromeric receptor composed of two EPO receptors
and one common -subunit (cR or CD131) [9,10].
Despite some controversy about the expression of EPO
receptor in the brain [11], the receptor for EPO has
been described as being expressed in neurons, glia,
and endothelial cells [12,13].
Side effects of chronic EPO administration related
to cardiovascular risk factors [14,15] and thrombocy-
topenia [16] reduce the clinical applicability of EPO
as a neuroprotective agent [17]. This has prompted
the search for molecules that do not have erythro-
poietic activity but conserve protective functions. The
carbamylated form of EPO (CEPO) is a class of
these molecules. Seven lysine residues of EPO are
carbamylated, a reaction naturally occurring during
bloodstream circulation [3,18,19]. CEPO and EPO
have been proven to cross the blood-brain barrier.
CEPO has been assayed in certain settings without
inducing changes in blood cell parameters [19,20].
EPO improves memory in a transgenic mouse model
of Alzheimer’s disease (AD) (Tg2576) and this effect
is associated with amyloid- (A) clearance [21].
In addition, its effect on erythroid precursors and
endothelial tissue can potentiate beneficial outcome
by improving blood supply and circulatory condi-
tions. However, the applicability of EPO in AD is
limited considering the appearance of undesirable side
effects linked to long-term treatment in chronic dis-
ease. Therefore, the present study explores the effects
of chronic EPO and CEPO in APP/PS1 mice in order
to evaluate the relevance of the specific features of
each molecule. Treatment effectiveness was measured
in terms of memory improvement, and mechanisms
involved were assessed by analyzing A, by perform-
ing mRNA microarrays, and by using quantitative PCR
and protein quantification in western blots.
MATERIALS AND METHODS
Animals
Male APP/PS1 transgenic mice and correspond-
ing wild-type (C57BL/6J) animals were obtained
from Jackson Laboratory (USA). The APP/PS1
model expresses a chimeric mouse/human APP
(Mo/HuAPP695swe: APP Swedish mutation) and a
mutant human presenilin 1 (PS1-dE9), both directed
to central nervous system neurons [22]. Animals were
maintained under standard animal housing conditions
in a 12 h dark–light cycle with free access to food
and water. Treatment started at the age of 5 months.
All the procedures concerning animal handling were
conducted according to ethical guidelines (European
Communities Council Directive 86/609/EEC) and
were approved by the local ethics committee.
Treatment
The carbamylated EPO molecule CEPO [19] was
obtained from Lundbeck (Denmark). EPO- (Neo-
Recormon, Roche, Germany) and CEPO were diluted
in isotonic solution (0.9% NaCl). Mice received
intraperitoneal (IP) volumes of 10 ml/kg containing
doses of 2,500 UI/kg of EPO, 2,500 UI/kg of CEPO, or
5,000 UI/kg of CEPO. A group of animals received an
equivalent volume (10 ml/kg) of vehicle (0.9% NaCl).
Doses were administered 3 days/week for 4 weeks.
Treatment is abbreviated as follows: Veh (for vehi-
cle), CE25 and CE50 (for treatment with 2,500 or
5,000 UI/kg of CEPO), and E25 (for treatment with
2,500 UI/kg of EPO). Body weight was measured each
administration day.
Memory test
Memory was assessed with the novel object recogni-
tion test. The test was performed in a V-maze (Panlab,
Barcelona, Spain) in which one object is placed at
the end of each arm. The V-maze consists of two
corridors (30 cm long × 4.5 cm wide, and 15 cm high
walls) set at a 90◦ angle [23]. The test is given during
two sessions (training and test) that start by placing
the animals on the vertex of the maze and in which
they are allowed to freely explore the maze for 9 min.
In the training sessions, the two objects are identical
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whereas in the test session one of the objects is replaced
by a different object. The ability of the animal to
remember the familiar object is an indicator of the
memory of the animal and is evaluated by calculating
the Discrimination Index (DI). The DI was calcu-
lated with the values recorded during the test session,
based on the time (T) that the animal spent explor-
ing the novel object (TN) versus the familiar object
(TF) : DI = (TN-TF)/(TN + TF). DI values of zero
indicate that the animal had no preference for explor-
ing one or the other object, while positive values are
given when the animal spent more time exploring the
novel object, indicating recognition of the familiar one.
Only animals that reached the minimum of 5 s of object
exploring time were included for data analysis and fur-
ther study. This threshold was previously established
with our colony as it allows discriminating between
WT and APP/PS1 memory phenotypes.
Tissue preparation
After the memory test, animals were deeply anaes-
thetized by intraperitoneal (0.2 mL/10 g body weight)
with a mixture of ketamine (100 mg/kg) and xylazine
(20 mg/kg).
Blood was extracted by intracardiac puncture and
collected in Vacuette® Blood collection tubes, K3
EDTA. Then animals were perfused with cold 0.1
M phosphate buffer (PB) with a peristaltic pump
at 19 mL/minute until blood was cleared from the
blood vessels. Brains were removed and divided
into two hemispheres. The left hemisphere was dis-
sected into different brain regions, immediately frozen
on dry ice and stored at −80ºC until needed. The
right hemisphere was fixed by immersion in 4%
paraformaldehyde (PFA) for 24 h after which PFA
was replaced by PBS 1x. Tissue was then dehydrated
by sequential immersion in ethanol at 70%, 96%,
and 100%, and xylene, before being embedded in
paraffin blocks. Sections 4-m-thick were obtained
with a Leica microtome for immunohistochemical
study.
Blood analysis
Blood parameters were acquired with a veterinary
analyzer (MEK-6318, Nihon Kohden). Reticulocyte
count was determined by cytometry after Thiazole
Orange (TO) (Sigma, USA) staining of 5l blood.
Briefly, blood was washed in 1 mL DPBS 1x (2.7
KCl; 1.5 mM KH2PO4; 8.1 mM Na2HPO4; 138 mM
NaCl), centrifuged, fixed for 10 min in 500l solu-
tion of 1% glutaraldehyde (Merck) and 0.003% SDS
(Sigma) in DPBS 1x, washed in 1 ml DPBS1x, cen-
trifuged and then stained in the dark for 30 min at
RT in 1 ml of staining solution containing 0.5g/ml
TO, 0.02% NaN3 (Merck, Germany) and 2 mM EDTA
in DPBS 1x. All centrifugation steps were 5 min and
800 g. After washing with DPBS1x, pellet was re-
suspended in 1 mL DPBS1x. 1/10 dilution was used
for cytometry analysis. A total of 105 events of the
cell population gate were acquired in a FACS Cal-
ibur cytometer (Becton Dickinson). The F1 negative
population was determined with an unstained sam-
ple, and TO+reticulocyte population was quantified.
Reticulocyte index was calculated with the reticulo-
cyte count (RC) and hematocrite count (HTC) and
the value of normal HTC (NHTC) of 45%: RI = RC ×
HTC/NHTC.
Evaluation of Aβ burden and Aβ soluble forms
Extracellular A deposition was quantified with A
immunostaining. Three non-overlapping paraffin coro-
nal sections (separated by at least a 40m gap) from
each animal were prepared backwards from Bregma
(−0.70 to −1.7 mm). Although this 1 mm spanning
of the brain sections may seem broad, there are no
differences between treatment groups regarding the
areas analyzed for amyloid burden as all distances
from Bregma are represented in each group. Paraf-
fin sections were de-waxed, treated for 3 min with
formic acid, boiled for 20 min in citrate buffer (8.2 mM
sodium citrate and 2 mM citric acid; pH 6), blocked
in PBS 1x with 3% serum normal horse for 1 h at
room temperature (RT), and stained with the A anti-
body clone 6F/3D (Dako, Denmank) overnight at
4ºC. Staining was visualized after biotin-streptavidin
labelling of primary antibody with the Universal
LSAB™+Kit/HRP (Dako, Denmank) and subsequent
incubations with diaminobenzidine (Sigma, USA) and
H2O2.
The quantification of the cortical area occupied by
the A plaques was done using the analysis tool avail-
able in the Adobe Photoshop CS5-Extended version.
The cerebral cortex area analyzed covered the motor
and somatosensory cortices, granular, dysgranular, and
agranular insular cortices, ectorhinal and perirhinal
cortices, piriform cortex and amygdaloid nucleus. The
cortex was outlined manually and its area quantified
(ACx). Plaques were automatically selected by color
and the selection was manually corrected. The sum of
plaque areas (AP) was automatically quantified by the
software. The A burden was obtained by calculating
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(AP /ACx) × 100 and the % A burden values were
normalized to the control group (Veh-treated) of ani-
mals of each treatment set.
Soluble non-fibrillar forms of A in cortical tis-
sue homogenate from nine APP/PS1 animals per
treatment group were quantified with A40 and A42
ELISA kits (Invitrogen, USA) following the man-
ufacturer’s instructions. Tissue was homogenized in
4 brain volumes (4l/mg) of chilled Tris Buffered
Saline (TBS; 140 mM NaCl, 3 mM KCl, 25 mM Tris-
HCl, 5 mM EDTA, pH 7.4) and complete EDTA-free
Mini protease inhibitor (Roche, Germany). Tissue was
homogenized with a Polytron (Kinematica, Switzer-
land) and then centrifuged at 100,000 g for 1 h at 4ºC.
Supernatant protein content was quantified with BCA
kit (Thermo scientific).
RNA microarray studies
RNA from frozen neocortex samples of treated mice
was extracted according to the manufacturer’s instruc-
tions (Rneasy Lipid Tissue Mini Kit, Qiagen® GmbH,
Hilden, Germany). RNA quality was checked with
the Agilent Bioanalyzer (Agilent Technologies Inc.,
Santa Clara, CA, USA) and the RNA concentration
was evaluated using a NanoDrop™ Spectrophotome-
ter (Thermo Fisher Scientific, Wilmington, DE, USA).
A total of 16 samples (6 APP/PS1-Veh, 5 APP/PS1-
CE50, and 5 APP/PS1-E25) were sent to the Unit
of High Technology at the Vall d’Hebron Research
Institute (Barcelona, Spain) for microarray hybridiza-
tion with the Affimetrix GeneChip® Mouse Gene
1.0 ST Array (Santa Clara, CA, USA). Microarrays
were pre-processed with a three (+1) step on the
probe values to turn them into comparable gene-level
expression values: background correction (RMA),
normalization (Quantiles), summarization (Median
Polish) and transcript-level summarization (Average).
Non-specific filtering was applied to remove con-
trols, low signal genes and low variability genes.
This pre-processing left 6,419 genes for further
study.
The selection of differentially expressed genes
between conditions was based on a linear model anal-
ysis with empirical Bayes moderation of the variance
estimates following the methodology developed by
Smyth [24]. The analysis yields standard test statistics
such as fold changes and (moderated)-t or p–values
which can be used to rank the genes from most to
least differentially expressed. Functional annotation
and biological term enrichment analysis were done
using the DAVID database [25,26].
Quantitative PCR
1g of total RNA from brain neocortex was reverse-
transcribed to cDNA with the High-Capacity cDNA
Reverse Transcription kit (Applied Biosystems).
Transcript level quantification of a particular gene was
performed in duplicate reactions with gene-specific
TaqMan® probes and the TaqMan Universal PCR
Master Mix (Applied Biosystems). The following Taq-
Man probes were used: Mm00802075 m1 (Adora2a),
Mm01328600 m1 (Adra1d), Mm01353211 m1
(Drd1a), Mm00438545 m1 (Drd2), Mm00432887 m1
(Drd3), Mm00456650 m1 (Egr2), Mm00612977 m1
(Grp), Mm01193520 m1 (Htr1d) and Mm01230885
m1 (Oprk1). Housekeeping gene probes were
Mm00507627 m1 (Aars), Mm01545399 m1 (Hprt),
and Mm00460040 m1 (Xpnpep1) [27]. QPCR was
performed using the Applied Biosystems 7900HT
Fast Real-Time PCR System. Ct values were obtained
by performing a relative quantification run using
the threshold value calculated automatically by the
SDS 2.2.2 software. Gene expression was calculated
with the double delta CT (CT) method using
vehicle-treated WT samples as reference group.
Western blotting
Five cerebral cortex samples per genotype and treat-
ment were analyzed with western blotting. Proteins
were extracted from frozen tissue with RIPA buffer
(50 mM Tris-HCl, pH8.0; 150 mM NaCl, 1% Non-
idet P-40; 0.5% Na-Deoxycholate; 0.1% SDS; 1 mM
PMSF; 1 mM Na3OV4) supplemented with protease
and phosphatase inhibitors (Roche, Germany), and
quantified with the Bradford reagent (Sigma, USA)
using bovine serum albumin (BSA) standard. Protein
samples were mixed with loading sample buffer (final
concentrations: 62.5 mM Tris, pH 6.8; 2% SDS; 10%
glycerol and 0.0025% bromophenol blue) and heated
at 95ºC for 5 min. 30g of proteins was separated
by electrophoresis in SDS-PAGE gels with 10% acry-
lamide and transferred to nitrocellulose membranes
(0.2m pore, BioRad). Membranes were incubated
with blocking buffer TBS-Tween (TBS-T; 10 mM
Tris; 140 mM NaCl and 1% Tween) with 5% non-
fatty milk for 1 h at RT. Membranes were incubated
overnight at 4◦C with primary antibodies (or for 1 h
at RT for -Actin): mouse anti-adenosine receptor
A2a (A2A) (Millipore), rabbit anti-dopamine recep-
tor 2 (DRD2), goat anti-dopamine receptor 1 (DRD1)
(Frontier Institute), and mouse anti--actin (Sigma).
Primary antibodies were diluted 1:1,000 (A2A, DRD1,
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and DRD2) or 1:30,000 (-Actin) in TBS-T with
0.05% NaN3 (Merck) and 5% non-fatty milk (A2A) or
3% BSA (Sigma, USA) (DRD1, DRD2, and -Actin).
Membranes were washed with TBS-T and incubated
for 1 h with their corresponding HRP-conjugated IgG
secondary antibody (Dako, Denmark) diluted 1:1,000
in blocking buffer. Immunoreactivity was visualized
by incubating the membranes with chemiluminescence
reagent (ECL, Amersham) and exposing Amersham
Hyperfilm ECL (GE Healthcare Lifesciences). Blot
quantification of each band (A2A, 50 kDa; DRD1
75 kDa, DRD2 100 kDa and -Actin 42 kDa) was
performed with Totallab software (TL100 v.2006b).
Bands were normalized to -actin levels.
Statistical analysis
Memory test and histological analysis were per-
formed blind to genotype and/or treatment. Grubbs’
test or ESD method (extreme studentized deviate) was
applied to determine significant outlier values. Statis-
tical significance of the data was evaluated with either
Student’s t-test or one-way ANOVA, followed by Dun-
nett’s post-test or two-way ANOVA, in turn followed
by Bonferroni post-tests. Data were analyzed and plot-
ted with the GraphPad Prism 5.01 software. In all
experiments the significance level was set at p < 0.05.
RESULTS
Effect of treatment on body weight and blood
parameters
WT and APP/PS1 animals were treated with Vehi-
cle, EPO (2,500 UI/kg), or CEPO (2,500 UI/ kg or
5,000 UI/ kg), hereafter referred to as Veh, E25, CE25,
and CE50, respectively. Given the chronicity of the
treatment, we analyzed whether body weight changes
occurred due to the treatment. Body weight control
during treatment showed that in WT animals, EPO
accounted for a slight but significant decrease in the
area under the curve (AUC) calculated with the %
values of the initial weight (F3.139 = 3.63; p < 0.05)
(Fig. 1A). No weight loss was found in APP/PS1-
treated animals with EPO and CEPO.
Given the erythropoietic properties of EPO, blood
parameters were controlled and differences between
treatments were analyzed. Blood from treated ani-
mals was collected and analyzed after performance
of the memory test. Mean values for each treatment
group are presented in Table 1. Two-way ANOVA
analysis indicated that treatment accounted for the
Fig. 1. A) Body weight during treatment is represented as the
% initial weight recorded for each administration day. Only WT
animals had a reduced weight when treated with EPO, as deter-
mined with two-way ANOVA and Bonferroni post-test of the area
under the curve calculated for each animal. The mean % weight
of each group at every administration day is represented. Devia-
tions from the mean are not represented for the sake of clarity.
B) Discrimination index of WT and APP/PS1 mice after treat-
ment with Vehicle (Veh), EPO (E25), or CEPO (CE25 and CE50).
The APP/PS1-Veh group shows memory defect compared to the
WT-Veh group ( symbol). We observe that APP/PS1 animals
show improved memory performance compared to the Veh-treated
APP/PS1 group after E25, CE25, and CE50 treatment (signifi-
cance indicated by ∗). Mean ± SEM are represented. E25: animals
treated with doses of 2500 UI/kg; CE25 and CE50: animals treated
with doses of 2,500 UI or 5,000 UI/kg, respectively. NWT-Veh = 14;
NAPP/PS1-Veh = 15; NWT-E25 = 16; NAPP/PS1-E25 = 12; NWT-CE25
= 14; NAPP/PS1-CE25 = 12; NWT-CE50 = 16; NAPP/PS1-CE50 = 9.
 = Genotype effect; ∗ = Treatment effect compared to Veh group;
∗p < 0.05,/∗∗p < 0.01. Two-way ANOVA followed by Bonferroni
post-test.
significant differences in variance observed and that
there was no interaction with genotype. Compared to
vehicle-treated animals, EPO induced similar changes
in the levels of red blood cells (RBC) (F3,59 = 11.7;
p < 0.0001) and HTC, hemoglobin (HB) (F3,59 = 15.10;
p < 0.0001), RC (F3,27 = 32.24; p < 0.0001), and retic-
ulotyte index (RI) (F3,27 = 22.73; p < 0.0001) in both
WT and APP/PS1 genotypes. Bonferroni post-
test indicated that RBC, HTC, and HB were all
significantly increased between 1.26 and 1.29-fold
(p < 0.001), and RC and RI were reduced by 82%
and 86% in WT (p < 0.001) and by 81% and 77%
in APP/PS1 (p < 0.001) mice, respectively. PLT
412 M. Armand-Ugo´n et al. / CEPO Improves Memory in the APP/PS1 FAD Model
Table 1
Blood parameters of animals after EPO or CEPO treatment
Wild type APP/PS1
Veh E25 CE25 CE50 Veh E25 CE25 CE50
WBC 2.0 ± 0.3 3.5 ± 0.9 1.9 ± 0.3 3.1 ± 0.6 3.1 ± 0.8 4.2 ± 0.6 2.6 ± 0.6 2.1 ± 0.6
RBC 9.0 ± 0.2 11.5 ± 0.4∗∗∗ 9.3 ± 0.2 9.7 ± 0.2 8.8 ± 0.4 11.0 ± 0.9∗∗∗ 9.4 ± 0.3 9.3 ± 0.2
HB 13.6 ± 0.3 17.5 ± 0.6∗∗∗ 14.0 ± 0.3 14.5 ± 0.4 13.1 ± 0.5 17.0 ± 1.2∗∗∗ 13.8 ± 0.5 13.4 ± 0.5
HTC 41.4 ± 0.7 53.5 ± 1.7∗∗∗ 42.8 ± 0.8 44.1 ± 1.1 40.9 ± 1.3 52.3 ± 3.6∗∗∗ 42.8 ± 1.0 42.4 ± 1.4
MCV 46.3 ± 0.6 46.6 ± 1.0 45.9 ± 08. 45.6 ± 0.6 46.8 ± 0.7 47.7 ± 1.3 45.5 ± 0.5 45.7 ± 0.4
MCH 15.2 ± 0.2 15.2 ± 0.3 15.1 ± 0.3 14.9 ± 0.2 15.0 ± 0.2 15.4 ± 0.4 14.6 ± 0.3 14.4 ± 0.3
MCHC 32.9 ± 0.3 32.5 ± 0.2 32.7 ± 0.4 32.8 ± 0.4 32.0 ± 0.5 32.4 ± 0.3 32.1 ± 0.7 31.7 ± 0.5
PLT 1110.2 ± 64.0 683.2 ± 94.3∗∗ 971.6 ± 93.2 1040.3 ± 99.3 1112.0 ± 66.9 724.0 ± 86.4∗ 816.6 ± 195.7 788.5 ± 130.2
RC 3.2 ± 0.2 0.6 ± 0.2∗∗∗ 3.2 ± 7 3.0 ± 0.2 3.0 ± 0.2 0.4 ± 0.2∗∗∗ 3.2 ± 0.5 2.3 ± 0.2
RI 3.1 ± 0.2 0.7 ± 0.2∗∗∗ 3.2 ± 0.8 2.9 ± 0.2 2.9 ± 0.2 0.6 ± 0.2∗∗∗ 3.1 ± 0.5 2.2 ± 0.2
Mean values ± SEM of white blood cells (WBC; 103/L), red blood cells (RBC; 106/L), hemoglobin (HB; g/dL), hematocrit (HTC; %),
mean corpuscular volume (MCV; fL), mean corpuscular hemoglobin (MCH; pg), mean corpuscular hemoglobin concentration (MCHC; g/dL),
platelets (PLT; 103/L), reticulocyte count (RC; %), and reticulocyte index (RI). Two-way ANOVA followed by Bonferroni post-test; Significance
compared to matching genotype Veh-treated group. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
was significantly reduced (F3.27 = 5.25; p = 0.003),
by 35%, in the WT-E25 (p < 0.01), and by 38% in
APP/PS1-E25 (p < 0.05). However, no modifications
in any of these parameters were observed in WT or
APP/PS1 animals after either CEPO treatment (CE25
or CE50) (Table 1). No modifications in the levels
of WBC (F3,57 = 2.69; p = 0.055), MCV (F3,57 = 1.19;
p = 0.321), MCH (F3,58 = 1.60; p = 0.199), and MCHC
(F3,58 = 0.13; p = 0.943) were observed among the
treated groups.
EPO and CEPO improve memory of AβPP/PS1
mice
At the end of the treatment, we tested the effect
of EPO and CEPO on the cognitive status of the
APP/PS1 mice. The memory of each group was
assessed with the novel object recognition test, and
subsequently the discrimination index (DI) was cal-
culated. As expected, we observed reduced memory
in the transgenic mice, and vehicle-treated WT and
APP/PS1 animals showed a DI of 0.33 ± 0.04 and
−0.01 ± 0.06, respectively. Two-way ANOVA anal-
ysis indicated that there was interaction between
treatment and genotype (F3,105 = 4.172, p = 0.0078).
Bonferroni post-test indicated that chronic treatment
with EPO (p < 0.05) and both doses of CEPO (CE25,
p < 0.05; and CE50 p < 0.01) significantly improved
memory of APP/PS1 animals to levels similar to WT
animals; yet EPO and CEPO had no effect on the DI
of WT animals (Fig. 1B).
EPO and CEPO effects on brain Aβ
Cognitive deficit in the APP/PS1 mice arising after
the processing of A is measurable. Soluble forms of
A40 and A42 can be detected and gradually increase
from the age of 3 to 6 months. A deposition is also
readily detectable in this region from 3 months of age
and the plaque burden increases during mouse lifetime
[28]. In order to learn whether the memory improve-
ment observed after EPO and CEPO treatments was
linked to a modulation of A processing, we evaluated
these two parameters in treated APP/PS1 groups.
A burden was quantified by immunohistochem-
istry in three non-overlapping coronal slices per
animal. The area covered by plaques in the cerebral
cortex was calculated with respect to the total cerebral
cortex area (see Materials and Methods section). Mean
A burden of APP/PS1-veh mice was 1.3%. This
value was reduced by 20% after treatment with EPO
(One-way ANOVA, F3.66 = 3.36; p < 0.05). In contrast,
CEPO did not produce any significant effect on A
burden (Fig. 2A). Sections from WT samples were all
negative for A immunoreactivity, as expected.
The TBS-soluble fraction of cortical tissue was
extracted and the amounts of A40 and A42 were
quantified by ELISA. Samples from WT animals were
negative for soluble A40 and A42. Compared to the
vehicle-treated APP/PS1 group, one-way ANOVA
showed that soluble A40 was reduced by EPO by
59% (Dunnett’s post-test; p < 0.05). The levels of
A42 showed a trend toward decrease in APP/PS1
animals treated with EPO (55% lower) and with
CEPO when administered at the highest dose (46%
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Fig. 2. Amyloid- in APP/PS1 mice after treatment with vehicle
(Veh), EPO (E25), or CEPO (CE25 and CE50). A) For each animal,
fibrillar A burden in plaques was quantified with immunohisto-
chemistry. Three non-overlapping coronal sections of the cerebral
cortex were analyzed. APP/PS1 animals treated with EPO had
lower burden than vehicle-treated APP/PS1 mice (∗p < 0.05; One-
way ANOVA and Dunnett’s post-test). Quantification of soluble A
forms: B) A40 and C) A42. EPO treatment reduced the levels
of the soluble A40 form compared to the control treatment (Veh).
(∗p < 0.05; One-way ANOVA and Dunnett’s post-test). Veh: vehicle-
treated animals; E25: animals treated with doses of 2,500 UI/kg;
CE25 and CE50: animals treated with doses of 2,500 UI or 5,000
UI/kg, respectively. Mean ± SEM values are represented.
lower) (Fig. 2B-C). No statistically significant differ-
ences were detected when comparing EPO and CEPO
treatments.
RNA microarray evidence that CEPO and EPO
have different signaling pathways
Our analysis of A in the neocortex of treated mice
indicated that EPO could modify the A processing,
whereas CEPO had little or no effect, thus indicat-
ing that EPO and CEPO may act on different targets.
Therefore, we decided to search for molecular routes
to differentiate the two treatments by gene expres-
sion using mRNA microarray. RNA was extracted
from the neocortex, as this is the brain region most
abundant in A plaques which start developing at the
age of 3 months [28]. We performed gene expression
microarray analysis of samples from APP/PS1-Veh
(n = 6), APP/PS1-E25 (n = 5), and APP/PS1-CE50
(n = 5). Gene expression profile in the APP/PS1-
vehicle group showed high individual variation. There
were 423 genes with significant (p < 0.05) changes in
expression between vehicle and CEPO or EPO-treated
groups (Fig. 3A), and log2 fold changes (log2 FC)
ranged between −1.59 and 0.95 when comparing E25
with Veh and −1.70 and 0.50 when comparing CE50
with Veh. Only 1.42% (6 genes) of these genes were
shared by EPO and CEPO (Fig. 3B).
Then we performed a comparative study of EPO and
CEPO treatments in APP/PS1 mice. Using a cut-off
value of p < 0.05, 514 genes had higher and 576 had
lower expression in EPO-treated animals compared
to CEPO-treated animals (Supplementary Table 1). In
order to find out which genes best differentiated each
treatment, we searched for the genes with log2 FC
higher than 1 or lower than -1 (equivalent to a dou-
bled or halved expression of the gene in CE50 with
respect to E25 treatment, respectively) (Fig. 3 C). This
comparison yielded a list of 50 genes (Table 2) that
were submitted to the DAVID database.
Functional annotations and clustering rendered a list
of 39 enriched terms (Table 3). The functional analy-
ses indicated that differences between EPO and CEPO
were related to dopamine, synaptic transmission, and
neuropeptide signaling, among others. Fifteen genes
were selected for the 20 most enriched functional terms
including 7 neurotransmitter receptor genes: adenosine
A2a receptor, Adora2a; adrenergic receptor alpha 1d
(Adra1d); dopamine (DA) receptors Drd1a, Drd2 and
Drd3; 5-hydroxytryptamine (serotonin) receptor 1D,
Htr1d and opioid receptor kappa 1, Oprk1. Microarray
data revealed higher transcript levels of all three DA
receptors in the animals treated with CE50 compared to
animals that received EPO. The -fold changes ranged
from 2.69 to 4.02 (Moderated-t, p < 0.05, Table 2).
The remaining eight non-neurotransmitter receptor
genes were related to neuropeptides and amidation, and
contained genes for proenkephalin (Penk), tachykinin
precursor 1 (Tac1), tachykinin receptor 1 (Tacr1),
vasoactive intestinal peptide (Vip), and gastrin releas-
ing peptide (Grp). Two genes related to retinoic acid
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Fig. 3. RNA microarray results and subsequent validation by Q-PCR. The microarray was performed and analyzed with samples of APP/PS1
mice from three treatment groups (Veh, E25, and CE50). A) Venn diagram showing the distribution of genes with different expression (p < 0.05)
in the comparisons of CE50 and E25 versus Veh and between CE50 and E25 treatments. B) Volcano plot with the Log10 of the p-value and the
Log2 fold change values calculated by comparing the expression of all the genes between CE50 and E25 treatments. Lines highlight the cut-off
values (p < 0.05 and Log2FC below -1 and above 1) used to select for the genes that best differentiate the treatments, which are located in both
the upper right and upper left quadrants. C) Microarray data validation. Expression of selected genes in the brain cortex of treated WT and
APP/PS1 mice was determined with Q-PCR on individual samples. Genes: Drd1, Drd2 and Drd3a (Dopamine receptors); Adora2a (Adenosine
receptor a2a); Adra1d (Adrenergic receptor a1d); Oprk1 (Opioid receptor κ1); Grp (Gastrin releasing peptide) and Vip (Vasoactive intestinal
peptide). Each bar represents the mean ± SEM of 11–16 samples, ∗ = significant with respect to Veh group;  = significant with respect to E25
group; ∗/p < 0.05; ∗∗/p < 0.01. Two-way ANOVA followed by Bonferroni post-test.
signaling were classified in the Zinc finger term; these
genes were retinoic acid receptor beta (Rarb) and
retinoid X receptor gamma (rxrg). The early growth
response 2 gene (Egr2) clustered with other genes in
15 out of the 39 terms related to synaptic plasticity, cell
differentiation, and learning and memory.
Given the role of inflammation [28,29] in this
mouse model, we checked whether inflammation-
related terms were selected among CEPO and EPO
treatments, and vehicle. No gene cluster related the
effect of CEPO or EPO treatments with a modulation of
inflammation. We also checked whether the olfactory
system was modulated by treatment as we had recently
described changes in the expression of some genes in
the neocortex of the APP/PS1 mice compared to WT
animals [30]. EPO but not CEPO showed a down-
modulation of the Gnal (guanine nucleotide binding
protein -activation activity polypeptide, olfactory
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Table 2
List of genes with highest expression-fold changes in the comparison of CEPO and EPO
Symbols A Gene name Entrez ID Log2 FC p-value
Serpina9 serine (or cysteine) peptidase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 9
71907 10402422 2.08 0.005
Drd2 dopamine receptor 2 13489 10585169 2.01 0.012
Adora2a adenosine A2a receptor 11540 10364030 1.93 0.009
Sh3rf2 SH3 domain containing ring finger 2 269016 10455299 1.89 0.007
Gpr149 G protein-coupled receptor 149 229357 10498441 1.74 0.018
Abi3bp ABI gene family, member 3 (NESH) binding protein 320712 10436304 1.71 0.003
Rgs9 regulator of G-protein signaling 9 19739 10392415 1.70 0.003
Drd3 dopamine receptor 3 13490 10435793 1.69 0.025
Rxrg retinoid X receptor gamma 20183 10351430 1.66 0.013
Slc10a4 solute carrier family 10 (sodium/bile acid
cotransporter family), member 4
231290 10522388 1.57 0.025
Ndst4 similar to N-deacetylase/N-sulfotransferase 4;
N-deacetylase/N-sulfotransferase (heparin
glucosaminyl) 4
64580 10495878 1.57 0.019
Tac1 tachykinin 1 21333 10536363 1.47 0.022
Htr1d 5-hydroxytryptamine (serotonin) receptor 1D 15552 10509238 1.46 0.003
Gpr6 G protein-coupled receptor 6 140741 10368780 1.45 0.008
Drd1a dopamine receptor D1A 13488 10409319 1.43 0.005
Isl1 ISL1 transcription factor, LIM/homeodomain 16392 10412335 1.38 0.032
Slc10a4/Gm5868 solute carrier family 10 (sodium/bile acid
cotransporter family), member 4
231290 10530499 1.36 0.031
Slc5a7 solute carrier family 5 (choline transporter), member 7 63993 10451838 1.29 0.038
Gpr88 G-protein coupled receptor 88 64378 10501622 1.28 0.010
Oprk1 opioid receptor, kappa 1 18387 10344653 1.27 0.006
Rarb retinoic acid receptor, beta 218772 10417713 1.26 0.008
Lrrc10b predicted gene 705 278795 10465963 1.23 0.034
Penk preproenkephalin 18619 10511363 1.23 0.016
Cdhr1 protocadherin 21 170677 10419015 1.23 0.003
Fam40b family with sequence similarity 40, member B 320609 10536949 1.19 0.006
Tcfap2d transcription factor AP-2, delta 226896 10345007 1.16 0.032
Tacr1 tachykinin receptor 1 21336 10539244 1.15 0.007
Epyc//Gm10754 ENSMUSG00000074776 13516 10372106 1.13 0.019
Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit
1B
19049 10380862 1.12 0.009
Car12 carbonic anyhydrase 12 76459 10586591 1.08 0.037
Ptpro protein tyrosine phosphatase, non-receptor type 15;
protein tyrosine phosphatase, receptor type, O
19277 10542414 1.03 0.012
Mir376b ENSMUSG00000076043 723934 10398408 1.03 0.031
Pde10a phosphodiesterase 10A 23984 10441680 1.02 0.004
Crabp1 cellular retinoic acid binding protein I 12903 10585438 1.01 0.033
Dchs2 similar to dachsous 2 isoform 2; predicted gene 6731 229459 10492774 1.01 0.026
Cbln1 cerebellin 1 precursor protein; similar to
precerebellin-1
12404 10580469 −1.00 0.003
Fos FBJ osteosarcoma oncogene 14281 10397346 −1.00 0.005
Glt8d2//Tdg glycosyltransferase 8 domain containing 2 74782 10371296 −1.03 0.006
Vip vasoactive intestinal polypeptide 22353 10367582 −1.03 0.004
Adra1d adrenergic receptor, alpha 1d 11550 10487886 −1.04 0.012
Tshz2 teashirt zinc finger family member 2 228911 10478928 −1.08 0.009
Satb2 special AT-rich sequence binding protein 2 212712 10354777 −1.20 0.026
Egr2 early growth response 2 13654 10363735 −1.20 0.005
Npas4 neuronal PAS domain protein 4 225872 10464905 −1.22 0.004
Neurod6 neurogenic differentiation 6 11922 10544936 −1.26 0.018
Rnf39 ring finger protein 39 386454 10445061 −1.34 0.004
Fezf2 Fez family zinc finger 2 54713 10417620 −1.35 0.003
Akr1c18 aldo-keto reductase family 1, member C18 105349 10407435 −1.48 0.003
Grp gastrin releasing peptide 225642 10456353 −1.79 0.001
Baiap2l1 BAI1-associated protein 2-like 1 66898 10535559 −2.61 0.016
Genes with significant (p < 0.05) difference in expression when comparing the expression in APP/PS1 mice treated with CE50 with respect to
E25. The log2 FC cut-off values were −1 and +1.
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Table 3
Functional annotation for genes differently modulated between CEPO and EPO
Category Term p-value Fold enrichment
BP Response to amphetamine <0.0001 100.7
SP G protein-coupled receptor <0.0001 35.6
MF Amine receptor activity <0.0001 31.3
IP Dopamine receptor 0.0001 236.8
BP Multicellular organismal response to stress 0.0001 40.8
BP Regulation of synaptic plasticity 0.0003 31.5
BP Transmission of nerve impulse 0.0003 10
BP Positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 0.0003 5.9
BP Positive regulation of transcription from RNA polymerase II promoter 0.0003 7.4
BP Regulation of catecholamine secretion 0.0004 94.4
BP Regulation of synaptic transmission, glutamatergic 0.0004 94.4
MF Amine binding 0.0007 21.8
BP Negative regulation of blood pressure 0.0008 70.8
BP Forebrain development 0.0009 11.3
BP Neuron projection morphogenesis 0.001 10.7
BP Synaptic transmission 0.0011 10.6
UP Cytoplasmic 0.0011 2.3
BP Response to endogenous stimulus 0.0012 10.3
UP DNA-binding 0.0015 3.2
BP Learning or memory 0.0015 17
SP Neuropeptide 0.0024 40.6
BP Blood circulation 0.0029 13.6
BP Circulatory system process 0.0029 13.6
BP Activation of adenylate cyclase activity by G-protein signaling pathway 0.003 35.4
SP Amidation 0.0042 30.4
BP Ion homeostasis 0.0066 6.4
BP Glial cell differentiation 0.0068 23.6
BP Axonogenesis 0.0084 9.3
SP Zinc finger 0.011 18.4
BP Telencephalon development 0.0147 15.7
BP Neuropeptide signaling pathway 0.0171 14.5
BP Response to drug 0.0215 12.9
BP Cell migration 0.0235 6.3
CC Axon 0.0253 11.7
BP Rhythmic process 0.0263 11.6
BP Axon guidance 0.0263 11.6
BP Negative regulation of multicellular organismal process 0.0273 11.3
BP Cellular ion homeostasis 0.0292 5.8
BP Regulation of neurogenesis 0.0452 8.6
Genes with differences in expression of at least two-fold when comparing microarray data from EPO and CEPO treatments (cutoff p < 0.05)
were analyzed with DAVID. The functional annotation clustering tool was used with default settings and highest classification stringency. Only
terms from GeneOntology (BP, biological process; MF, molecular function; CC, cellular component), Interpro (IP) and SP PIR KEYWORDS
(SP) are included.
type) gene (log2 FC of −0.57, p = 0.022) (Supplemen-
tary Table 1). Although the function of this system
in non-olfactory tissue is still unknown, this gene has
been found to be upregulated in APP/PS1 mice at the
age of 3 months followed by a return to WT levels at
the age of 6 months [30].
Microarray validation
We selected genes to validate the microarray data
by performing quantitative PCR on individual samples
obtained from treated animals. Gene expression was
evaluated in both WT and APP/PS1-treated animals
that had received Veh, CE25, CE50, and E25 treat-
ment. Given the greater variability in the control group
as analyzed by microarray, we increased the sample
size for this validation step in order to boost the statis-
tical power of the ANOVA test. QPCR was performed
to validate the mRNA expression of neurotransmitter
receptor and neuropeptide genes. These were seven
neurotransmitter receptors (Adora2a, Adra1d, Drd1a,
Drd2, Drd3, Htr1d, and Oprk1) and two neuropeptides
(Grp and Vip). We also evaluated the expression of
transcription factor Egr2, as it also was differently
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Fig. 4. Analysis of the protein levels of the neurotransmitter receptors A2AR, D1R, and D2R. A) Western blots of the three antibodies and the
loading control (-actin). Three representative samples per genotype and group are shown. B) Bar diagram of the quantification of the blots.
Two-way ANOVA analysis followed by Bonferroni post-test indicated that there was a genotype effect () with protein levels always lower in
the APP/PS1 mice compared to the WT mice. A2AR levels were reduced after CE50 treatment in the WT mice. D1R and D2R protein levels
were increased with CEPO treatment in both genotype groups. D2R was decreased by EPO in the WT mice. Bars represent the mean ± SEM of
five samples per group and genotype, from two-three independent blots. To join data from different blots, values were calculated with respect
to the mean of the WT-Veh group; A.U. arbitrary units. ∗p < 0.05; ∗∗p < 0.01; and ∗∗∗/p < 0.001, as indicated by two-way ANOVA and
Bonferroni post-test.
modulated by EPO and CEPO (Table 2); Egr2 has
previously been related to acute EPO signaling after
experimental stroke in vitro and in vivo [31]. All the
data from the QPCR assays are shown in Fig. 3C.
Considering crossed comparisons between WT and
APP/PP1 mice treated with vehicle, EPO, CE25,
and CE50, two-way ANOVA analysis indicated that
treatment accounted for differences in the expression
of Drd1a (F3,80 = 11.37; p < 0.0001), Drd2 (F3,80 = 7.8;
p = 0.0001), Drd3 (F3,66 = 6.98; p = 0.0004), Adora2a
(F3,78 = 9.27; p < 0.0001), Adra1d (F3,76 = 8.23;
p < 0.0001), Oprk1 (F3,66 = 3.74; p = 0.0152), Grp
(F3,75 = 7.75, p < 0.0001), and Vip (F3.75 = 7.95,
p < 0.0001). Under our experimental conditions,
Htr1d expression was at the limit of detection and the
analysis by QPCR could not be completed. Regarding
Egr2, qPCR did not validate the differences observed
in the microarray (F3.72 = 0.95; p = 0.419) (not shown
in Fig. 3C).
Comparted to VEH-treated animals, Bonferroni
post-test showed that CEPO (CE25 and CE50) sig-
nificantly increased the expression of Drd1 in WT
(CE25 p < 0.05; CE50 p < 0.001) and APP/PS1
(CE25 p < 0.05; CE50 p < 0.05) mice whereas Drd2
and Adora2a were significantly increased only with
CE50 in WT (Drd2 p < 0.01; Adora2a p < 0.01) but
not in APP/PS1 transgenic mice. CEPO signifi-
cantly decreased the expression of Adra1d in WT (at
doses of CE50; p < 0.001) and APP/PS1 (at doses of
CE25; p < 0.05), and Grp at CE25 (p < 0.01) and CE50
(p < 0.01) doses in APP/PS1 but not in WT animals
(Fig. 3C). Additionally, EPO had no effect on the ana-
lyzed genes excepting a significant increase of Vip in
WT (p < 0.01) but not in APP/PS1 transgenic mice
(Fig. 3C). For the purpose of validation only, addi-
tional significant differences (labelled with) between
EPO and CEPO values are indicated in the same fig-
ure. Details of the statistical analysis of Q-PCR data
are summarized in Supplementary Table 2.
Protein quantiﬁcation of A2A, D1 and D2
neurotransmitter receptors
The results of RNA expression indicated that CEPO
treatment induces changes in the expression of certain
neurotransmitter receptor genes, most significantly the
genes coding for the adenosine receptor a2a (A2AR)
and the dopamine receptors 1 and 2 (D1R and D2R).
In order to learn whether this change in expression
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was translated to different protein levels, western blot
analysis of these three receptors was performed in the
different groups of animals (Fig. 4).
Protein levels of all three receptors were lower in
the APP/PS1 mice compared to the WT mice as indi-
cated by two-way ANOVA analysis of the blots of
A2AR (F1,32 = 53.10; p < 0.0001), D1R (F1,32 = 61.82;
p < 0.0001), and D2R (F1,32 = 123.21; p < 0.0001). If
we compare the mean expression of the WT-Veh
and APP/PS1-VEH groups, the protein expression
levels of A2AR, D1R and D2R were 72.0%, 51.9%
and 53.3% lower, respectively. There was a statis-
tically significant treatment effect on the levels of
A2AR (F3,32 = 3.30; p = 0.0326), D1R (F3,32 = 10.04;
p < 0.0001), and D2R (F3,32 = 23.70; p < 0.0001). Bon-
ferrroni post-test revealed that A2AR levels were
down-modulated in the WT animals by CE50 treatment
(p < 0.01), reduced by 42.2%. On the other hand, D1R
levels were increased by 34.1% and 31.8% in the WT
animals after CE25 and CE50 treatment, respectively
(p < 0.05). In the APP/PS1-CE50 group, the levels
of D1R were 55.6% higher than the APP/PS1-Veh
(p < 0.001), reaching levels similar to those for WT-
Veh. CEPO also induced an increment of D2R levels in
both WT and APP/PS1 mice. Compared to their Veh-
treated counterparts, CE25 and CE50 increased D2R
by 21.2% (p < 0.05) and 34.7% (p < 0.001) in the WT
mice, and by 48.3% (p < 0.05) and 72.2% (p < 0.001) in
the APP/PS1 mice, respectively. The only significant
effect of EPO compared to Veh-treated animals was
detected in the levels of D2R in the WT mice, which
showed 23.3% lower (p < 0.05) D2R levels. Details of
the statistical analysis of western blot data are summa-
rized in Supplementary Table 3.
DISCUSSION
The present results show that CEPO and EPO
improve the memory of APP/PS1 transgenic mice.
As expected, blood parameters related to red blood
cell production RBC, HTC, HB, and RI are modified
after treatment with EPO. We also observed a decrease
in the platelet cell population by EPO, which has been
previously reported as related to stem-cell competi-
tion between erythroid and platelet precursors [16].
Reduced body weight by EPO was observed in WT
mice, an observation which is in accordance with pre-
vious studies showing reduced body weight by EPO
in models of obesity [32], and in C57Black/C trans-
genic mice expressing EPOs that reduce lipid mass
by increasing muscle fat oxidation and upregulating
genes related to thermogenesis [33]. In contrast, the
present study demonstrates that CEPO has no delete-
rious effects on body weight and blood parameters in
WT and APP/PS1 transgenic mice. Therefore, CEPO
stands a better chance of being used as a putative ther-
apeutic agent administered during long periods.
Interestingly, EPO decreases fibrillar amyloid bur-
den (plaques) and soluble A40 in brain of transgenic
mice. Similar effects of EPO on A levels have also
been observed in the Tg2576 mouse model of AD [21].
However, CEPO has no effect on A plaque burden or
A soluble A. These novel findings suggest that the
effects of EPO and CEPO on behavior have different
molecular substrates.
RNA microarray assays followed by PCR validation
were carried out to identify putative targets of CEPO.
Microarray data reveal a limited number of common
genes modulated by EPO and CEPO, suggesting diver-
gent signaling routes. These different mechanisms of
action may be due to different molecular properties
of the primary compounds and to different receptors
(or conformation of the same receptors) for EPO and
CEPO [9,10]. Previous studies on the brain transcrip-
tome of the APP/PS1 mouse described age-related
changes associated with immune pathways [29] and
the olfactory receptor system [30]. Yet our microar-
ray data from APP/PS1-treated mice did not indicate
that CEPO or EPO had major effects on the expres-
sion of genes related to immune processes. In contrast,
the expression of certain neurotransmitter receptors
appeared to be upregulated by CEPO. Moreover, after
validating the selected genes, most of the observed
treatment-associated changes regarding neurotrans-
mitter receptors were similarly present in WT and
APP/PS1 mice.
Significant upregulation of the transcript of
dopamine receptors Drd1a, Drd2 and Drd3, and
adenosine receptor 2a, Adora2a, together with signif-
icant down-regulation of the adrenergic receptor 1D
(Adra1d), are discriminate CEPO and EPO treatments;
the effects of CEPO have no similar correspondence
in animals treated with EPO. Therefore, Drd1a, Drd2,
Drd3, Adora2a, and Adra1d are identified for the first
time as primary brain targets of CEPO.
Western blotting reveals lower protein levels of
all the receptors analyzed in APP/PS1 mice when
compared to controls, which is in agreement with
earlier observations showing reduced protein transla-
tion and altered synaptic protein levels in this mouse
model [34]. Moreover, western blotting demonstrates
that CEPO reduces this difference regarding the lev-
els of D1R and D2R. In contrast, increased RNA
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levels of Adora2a are not linked to increased A2AR
protein levels. Neurotransmitter receptors can het-
eromerize in a variety of combinations [35] leading
to modifications of the intracellular signal elicited by
ligand binding. Adenosine or dopamine binding to a
A2AR-D2R heteromer results in the intracellular antag-
onism of the other ligand [36]. Furthermore, D1R and
D2R heteromers have been described as modulating
the calcium/calmodulin-dependent protein kinase II
(CaMKII) in the striatum, and a role has been sug-
gested in synaptic plasticity [37]. In this line, it would
be interesting to learn whether the observed down-
regulation of A2AR and upregulation of D1R and D2R
after CEPO treatment affects heteromer arrangements.
Compared to Veh-treated APP/PS1 animals,
Adra1d and Grp were two other genes that were both
down-modulated by CEPO. Mice lacking Adra1d have
been associated with lower locomotor responses to
behavioral activation [38], and upregulation of Adra1d
transcripts have been recorded in the dentate gyrus in
response to stress [39]. On the other hand, Grp has
been related to fear-associated memory [40] but also
with opposite effects on neurogenesis and neuronal
development, as low GRP peptide levels are associ-
ated with increased neurogenesis but also with low
neuronal development [41]. It is, however, too soon
to speculate about the possible effects of Adra1d and
Grp down-regulation in the present setting.
The present observations support the value of CEPO
as a protective agent in the prevention of memory loss
in AD-related models, and they may have practical
implications in the treatment of AD. The beneficial
effect can be related to modulation of neurotransmis-
sion. This would agree with the concept of different
receptors for each, and in vitro and in vivo studies that
have observed differences between CEPO and EPO
[9,10,20]. Furthermore, the present results indicate that
CEPO is not merely an equivalent of EPO without ery-
thropoietic properties, but rather a different compound
with different molecular targets.
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